You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):利尿劑“螺內酯片”獲批新增適應症
格隆匯 09-15 16:43

格隆匯 9 月 15日丨中國生物製藥(01177.HK)發佈公告,集團研製的利尿劑“螺內酯片”(商品名:利夫萊)已獲國家藥品監督管理局頒發藥品補充申請批准通知書,批准增加100mg規格(為該品種首家國產規格)及新增適應症,用於治療心力衰竭、高血壓、與肝硬化或腎病綜合症相關的水腫、原發性醛固酮增多症。

根據披露,螺內酯為醛固酮競爭性抑制劑,作用於腎遠曲小管和集合管,利尿作用緩慢而持久,被包括2019年版《慢性心力衰竭基層診療指南》在內的多部國內診療指南一致推薦使用於治療心力衰竭和高血壓,主要適用科室有心血管內科、肝內科、腎內科、內分泌科、泌尿科等。螺內酯片已被納入2019年版國家醫保目錄(甲類)及2018年版國家基藥目錄。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account